BioXcel Therapeutics, Inc.BTAI
Market cap
$11.39M
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 0 | 0 | 0 | 0 | - | - | - |
| Stock-based compensation | 3 | 3 | 15 | 19 | 17 | 19 | 6 |
| Cash from operations | -14 | -27 | -66 | -82 | -135 | -155 | -72 |
| Capital expenditures | -0 | -1 | -0 | -0 | -0 | -0 | - |
| Cash from investing | -0 | -1 | -0 | -0 | -0 | -0 | - |
| Repurchases of common stock | - | - | 9 | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | - | - | 99 | - | - |
| Repayments of term debt | - | - | - | - | - | - | 3 |
| Cash from financing | 56 | 18 | 247 | 102 | 96 | 27 | 37 |
| Free cash flow | - | ||||||
| FCF margin (%) | - | - | - | - | - |